19:46 , Sep 12, 2018 |  BC Extra  |  Company News

Management tracks: Clearside, ImCheck

Clearside Biomedical Inc. (NASDAQ:CLSD) hired Leslie Zacks as general counsel and chief compliance officer. He was VP, general counsel and chief compliance officer at Arbor Pharmaceuticals Inc. (Atlanta, Ga.). Clearside plans to submit an NDA...
22:12 , Sep 15, 2017 |  BioCentury  |  Finance

Orphan opportunity

Private equity giant KKR returned to co-lead BridgeBio Pharma LLC 's $135 million venture round, which could enable the Orphan play to double its pipeline in the next two years. KKR co-led the Sept. 13...
23:50 , Jul 27, 2017 |  BC Week In Review  |  Clinical News

FDA approves Triptodur for central precocious puberty

Debiopharm Group (Lausanne, Switzerland) and Arbor Pharmaceuticals LLC (Atlanta, Ga.) said FDA approved Triptodur triptorelin to treat pediatric patients ages ≥2 with central precocious puberty. The companies plan to launch the product in 4Q17. Triptodur...
01:05 , Feb 16, 2017 |  BC Innovations  |  Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

XenoPort, Arbor Pharmaceuticals deal

Specialty pharma Arbor will acquire XenoPort for $7.03 per share in a cash deal the companies say values XenoPort at $467 million. The price is a 60% premium to XenoPort’s close of $4.40 on May...
00:21 , May 24, 2016 |  BC Extra  |  Company News

Arbor acquiring XenoPort

Specialty pharma Arbor Pharmaceuticals Inc. (Atlanta, Ga.) is acquiring XenoPort Inc. (NASDAQ:XNPT) for $7.03 per share, or about $467 million. The deal will give Arbor rights to Horizant gabapentin enacarbil , which is approved in...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Company News

Ampio genitourinary news

Ampio will spin off its sexual dysfunction business into newco Vyrix Pharmaceuticals Inc. The newco will be funded through an IPO that Ampio expects could take up to 12 months to complete. Ampio expects to...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

Arbor Pharmaceuticals, Takeda sales and marketing update

Takeda granted Arbor's Arbor Pharmaceuticals Ireland Ltd. subsidiary exclusive rights to commercialize hypertension drugs Edarbi azilsartan medoxomil and Edarbyclor azilsartan medoxomil/chlorthalidone in the U.S. Takeda, which has already launched the products in the U.S., will...
07:00 , Jul 18, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Seizures Calcium channel voltage-dependent L type-a 1C subunit (CACNA1C; Cav1.2) Rodent and cell culture studies suggest inhibiting Cav1.2 could help treat...
07:00 , May 20, 2013 |  BC Week In Review  |  Clinical News

Nymalize nimodipine regulatory update

Arbor said FDA approved an NDA for Nymalize nimodipine oral solution to improve neurological outcomes in adult patients with subarachnoid hemorrhage. The company plans to launch the product "in the next few months." Nimodipine is...